Imunon, Inc. (IMNN)
NASDAQ:IMNN
Want to see IMNN full AI Analyst Report?
IMNN Stock Chart & Stats
$3.10
-$0.06(-6.43%)
At close: 4:00 PM EST
$3.10
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$2.04 - $27.65
Previous CloseN/A
Volume151.93K
Average Volume (3M)45.91K
Market Cap
$8.82M
Enterprise Value$1.61M
Total Cash (Recent Filing)$4.79M
Total Debt (Recent Filing)$911.75K
Price to Earnings (P/E)―
Beta-0.79
Next Earnings
Aug 06, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.16
Shares Outstanding4,202,118
10 Day Avg. Volume63,197
30 Day Avg. Volume45,906
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market Cap0.18
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.22
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
$15.67Price Target Upside405.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.33
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy (OVATION II)A ~14.7-month median overall survival advantage is a durable, clinically meaningful efficacy signal that materially raises the program's probability of regulatory success and commercial relevance in advanced ovarian cancer. Strong survival data underpin long-term partner interest, labeling potential, and strategic optionality beyond short-term market noise.
Phase III Progress & EnrollmentActive patient randomization and site-level momentum reduce execution risk for the pivotal program. Demonstrable enrollment progress and engaged investigators improve the likelihood of timely data maturation, make operational planning more credible, and support constructive partner discussions and financing options over the coming 2–6 months.
Structured Non-dilutive Financing SecuredA $10M financing that limits traditional equity dilution provides immediate, structural runway to fund pivotal enrollment and start-up costs. Access to alternative, structured capital demonstrates financing flexibility, reduces near-term dilution pressure, and increases the company's ability to execute OVATION III without immediate large equity raises.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow means the company remains dependent on external capital to fund operations. This structural funding need increases dilution and execution risk, constrains discretionary R&D and commercialization planning, and requires continued access to financing over the medium term.
Long Pivotal TimelineA last‑patient target in Q1 2029 implies a prolonged period before definitive data and potential regulatory filings. This delays revenue realization, lengthens cash burn exposure, and increases the chance that external factors (competition, regulatory shifts, or financing market cycles) will affect the program's commercial and strategic outlook.
Near-zero Revenue & Large Recent LossMinimal recurring revenue and a materially large trailing loss reflect limited capital efficiency and no product-derived cash flow. These structural profitability deficits mean operations and growth hinge on financing or partnerships, reducing balance-sheet resilience and elevating dilution or restructuring risk over the next several quarters.
Imunon News
IMNN FAQ
What was Imunon, Inc.’s price range in the past 12 months?
Imunon, Inc. lowest stock price was $2.04 and its highest was $27.65 in the past 12 months.
What is Imunon, Inc.’s market cap?
Imunon, Inc.’s market cap is $8.82M.
When is Imunon, Inc.’s upcoming earnings report date?
Imunon, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 62 days.
How were Imunon, Inc.’s earnings last quarter?
Currently, no data Available
Is Imunon, Inc. overvalued?
According to Wall Street analysts Imunon, Inc.’s price is currently Undervalued.
Does Imunon, Inc. pay dividends?
Imunon, Inc. does not currently pay dividends.
What is Imunon, Inc.’s EPS estimate?
Imunon, Inc.’s EPS estimate is -0.99.
How many shares outstanding does Imunon, Inc. have?
Imunon, Inc. has 4,202,118 shares outstanding.
What happened to Imunon, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Imunon, Inc.?
Currently, no hedge funds are holding shares in IMNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon, Inc.
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
IMNN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong, potentially transformative clinical data (a ~14.7-month median OS benefit from OVATION II), clear enrollment momentum and favorable safety/translation signals, supported by an active plan to present additional data and to pursue investor-friendly financing. Counterbalancing these positives are a challenging capital market, a materially prolonged Phase III enrollment and readout timeline (last patient expected Q1 2029), and increased near-term cash burn driven by trial start-up costs. Management has outlined a restructuring and creative financing approach to conserve cash and limit dilution, and investor interest appears constructive. Overall, the clinical progress and enrollment momentum materially support upside potential, while financing and timeline risks remain meaningful near-term headwinds.View all IMNN earnings summariesIMNN Stock 12 Month Forecast
Average Price Target
$15.67
▲(405.38% Upside)
Technical Analysis
Ownership Overview
1.65% Insiders
0.94% Mutual Funds
9.11% Other Institutional Investors
87.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---